Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
Related Experiment Video
Updated: Dec 7, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Theresa Klümper1, Henrike Bruckmueller1, Tobias Diewock1
1Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
Background:
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substantially improved patients' prognosis, drug resistance remains one of the major challenges in CML therapy. MicroRNAs (miRNAs), a class of short non-coding RNAs acting as post-transcriptional regulators, are implicated in CML progression and drug resistance. The aim of the present study was to analyze the miRNA expression profiles of 45 treatment-naïve CML patients in chronic phase (28 peripheral blood and 17 bone marrow samples) with respect to future response to imatinib therapy.
Methods:
TaqMan low density arrays were used to analyze the miRNA expression pattern of the patient samples. For selected microRNAs, reporter gene assays were performed to study their ability to regulate CML associated target genes.
Results:
Significant lower expression levels of miR-142-5p were identified in both, peripheral blood and bone marrow samples of future non-responders suggesting a potential tumor suppressor role of this miRNA. This was supported by reporter gene assays that identified the survival, proliferation and invasion promoting CML related genes ABL2, cKIT, MCL1 and SRI as targets of miR-142-5p and miR-365a-3p, the latter identified as potential biomarker in peripheral blood samples.
Conclusion:
MiR-142-5p and to a certain extend also miR-365a-3p were able to discriminate treatment-naïve CML patients not responding to imatinib in the course of their treatment from patients, who responded to therapy. However, further large-scale studies should clarify if the identified miRNAs have the potential as predictive biomarkers for TKI resistance.
Insights
Lower expression of miR-142-5p and miR-365a-3p in chronic myeloid leukemia (CML) patients may predict resistance to imatinib therapy. These microRNAs could serve as biomarkers for treatment response in CML.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by BCR-ABL1 tyrosine kinase activity.
- Tyrosine kinase inhibitors (TKIs) have improved CML prognosis, but drug resistance remains a significant challenge.
- MicroRNAs (miRNAs) are implicated in CML pathogenesis and the development of TKI resistance.
Purpose of the Study:
- To analyze miRNA expression profiles in treatment-naïve chronic phase CML patients.
- To correlate miRNA expression with future response to imatinib therapy.
- To investigate the role of specific miRNAs in regulating CML-associated genes.
Main Methods:
- MicroRNA expression patterns were analyzed using TaqMan low-density arrays in 45 treatment-naïve CML patients (28 peripheral blood, 17 bone marrow).
- Reporter gene assays were conducted for selected miRNAs to assess their regulatory function on CML-associated target genes.
Main Results:
- Significantly lower expression of miR-142-5p was observed in both peripheral blood and bone marrow of future imatinib non-responders, suggesting a tumor suppressor role.
- Reporter gene assays identified ABL2, cKIT, MCL1, and SRI as targets of miR-142-5p and miR-365a-3p, genes involved in CML cell survival, proliferation, and invasion.
- miR-365a-3p was identified as a potential biomarker in peripheral blood samples.
Conclusions:
- miR-142-5p and miR-365a-3p can discriminate between treatment-naïve CML patients who will or will not respond to imatinib.
- These miRNAs show potential as predictive biomarkers for TKI resistance in CML.
- Further large-scale studies are warranted to validate their predictive potential.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation

